מדינה: קנדה
שפה: אנגלית
מקור: Health Canada
INSULIN INJECTION HUMAN BIOSYNTHETIC; INSULIN ISOPHANE HUMAN BIOSYNTHETIC
ELI LILLY CANADA INC
A10AD01
INSULIN (HUMAN)
30UNIT; 70UNIT
SUSPENSION
INSULIN INJECTION HUMAN BIOSYNTHETIC 30UNIT; INSULIN ISOPHANE HUMAN BIOSYNTHETIC 70UNIT
SUBCUTANEOUS
3ML
Schedule D
INSULINS
Active ingredient group (AIG) number: 0223312003; AHFS:
APPROVED
1997-12-10
_HUMULIN Product Monograph _ _ _ _Page 1 of 54_ PRODUCT MONOGRAPH HUMULIN ® R (insulin, human biosynthetic) Solution for Injection, 100 units/mL ATC Code: A10AB01 fast-acting HUMULIN ® N (insulin isophane, human biosynthetic, rDNA origin) Suspension for Injection, 100 units/mL ATC Code: A10AC01 intermediate-acting HUMULIN ® 30/70 (30% insulin injection, 70% insulin isophane, human biosynthetic, rDNA origin) Suspension for Injection, 100 units/mL ATC Code: A10AD01 intermediate- or long-acting combined with fast-acting THERAPEUTIC CLASSIFICATION ANTI-DIABETIC AGENT Eli Lilly Canada Inc. Exchange Tower 130 King Street West, Suite 900 P.O. Box 73 Toronto, Ontario M5X 1B1 Submission Control № 245812 Date of Initial Approval: December 31, 1983 Date of Revision: March 26, 2021 _HUMULIN Product Monograph _ _ _ _Page 2 of 54_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ...................................................... 3 SUMMARY PRODUCT INFORMATION ..................................................................... 3 INDICATIONS AND CLINICAL USE .......................................................................... 3 CONTRAINDICATIONS ............................................................................................... 4 WARNINGS AND PRECAUTIONS .............................................................................. 4 ADVERSE REACTIONS ............................................................................................... 9 DRUG INTERACTIONS ............................................................................................... 9 DOSAGE AND ADMINISTRATION .......................................................................... 10 OVERDOSAGE ........................................................................................................... 12 ACTION AND CLINICAL PHARMACOLOGY ......................................................... 12 STORAGE AND STABILITY ..................................................................................... 13 SPEC קרא את המסמך השלם